Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was CNY 147.65 million compared to CNY 189.15 million a year ago. Net income was CNY 2.35 million compared to CNY 8.79 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.79 HKD | +0.56% | -1.10% | -29.80% |
21/06 | Fudan Zhangjiang Bio-Pharmaceutical Enrolls First Patient for Glioma Drug Trial | MT |
21/06 | Shanghai Fudan Zhangjiang Bio-Pharmaceutical Terminates Libod Marketing Agreement | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-29.80% | 701M | |
+7.39% | 72.09B | |
+15.93% | 9.05B | |
-22.81% | 4.4B | |
+17.59% | 4.39B | |
+25.93% | 3.94B | |
+4.64% | 2.1B | |
+9.09% | 1.97B | |
-36.86% | 1.87B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- 1349 Stock
- News Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024